Study Finds Loss of Normal Nighttime Parasympathetic Activity in Veterans Suffering from Gulf War Syndrome

Los Angeles, December 12, 2012 — A scientific paper confirming the relationship between autonomic nervous system dysfunction and Gulf War Illness was published online  November 26, 2012  in the Archives of Neurology, according to Targeted Medical Pharma, Inc. (OTCQB: TRGM) (OTCBB: TRGM), a specialty pharmaceutical company that develops and distributes prescription medical foods to physicians and pharmacies.

The paper, “Cholinergic Autonomic Dysfunction in Veterans with Gulf War Illness,” revealed a blunting or loss of normal nighttime parasympathetic activity in veterans suffering from Gulf War Illness was strongly associated with upper gastrointestinal dysmotility and sleep dysfunction.  The abstract of the study can be viewed by visiting: http://bit.ly/CholinergicAutonomicDysfunctionStudy.

“The results of this study confirm our company’s approach to the management of Gulf War Illness and other diseases involving disordered autonomic function,” said William Shell, M.D., CEO and chief scientific officer of Targeted Medical Pharma, Inc., co-author of the scientific paper who provided data, analysis, and manuscript revisions  along with the late Elizabeth Charuvastra, RN, co-founder of Targeted Medical Pharma. “Our company is poised to educate military and civilian healthcare providers how to utilize the prescription-only medical foods Sentra AM® and Sentra PM® as part of a regimen to manage autonomic dysfunction associated with Gulf War Illness and other chronic diseases.”

The scientific paper was primarily designed and implemented by Dr. Robert W. Haley, chief of epidemiology at the University of Texas Southwestern Medical Center, and Dr. Steven Vernino, chief of the neuromuscular division at the University of Texas Southwestern Medical Center.

“This is the first study to establish a medical basis for symptoms of Gulf War Illness in a large, representative sample of veterans using validated medical tests,” said Dr. Haley, principal author of the paper.  “It now gives physicians a medical condition they can test for and treat.”

Funded by the U.S. Department of Veterans Affairs, U.S. Army Medical Research and Material Command, and the National Institute of Health, the study looked at 97 Gulf War-era veterans who met the standardized case definition of Gulf War Illness. The authors of prior studies raised the hypothesis that symptoms in veterans of the 1991Gulf War, such as chronic diarrhea, dizziness, fatigue, and sexual dysfunction, are due to cholinergic autonomic dysfunction.

About Targeted Medical Pharma, Inc.’s Medical Foods

Targeted Medical Pharma’s medical foods are amino acid based, FDA-regulated medications specially formulated to meet the body’s increased nutritional requirements of certain disease states.  They are a safe and effective option for treating pain syndromes, sleep and cognitive disorders, obesity, hypertension and peripheral neuropathy without harmful side effects.  These medical foods are available by prescription only and must be administered under the ongoing supervision of a physician.

The company recently published results from a clinical trial of its proprietary medical food Sentra PM, which demonstrated improved sleep latency and improved nighttime parasympathetic nervous system activity as a standalone medication or used in conjunction with a low dose of Trazadone. The results of the study have been published in the May issue of the Journal of Central Nervous System Disease (http://bit.ly/SentraPM_Study).

Targeted Medical Pharma, Inc.

Targeted Medical Pharma, Inc. is a specialty pharmaceutical company that develops and sells prescription medical foods to physicians and pharmacies for the treatment of chronic disease including pain syndromes, obesity, peripheral neuropathy, sleep and cognitive disorders.  The company manufactures ten proprietary prescription-only medical foods, as well as 48 convenience packed kits, which pair a medical food and branded or generic pharmaceutical.  These prescription medical food products and therapeutic systems represent a novel approach to the management of certain disease states, focusing on safety and efficacy without the deleterious side effects of traditional, high dose prescription drugs.  Based in Los Angeles, the company’s proprietary pharmaceutical therapeutic systems are currently sold in the United States and the Middle East.  Targeted Medical Pharma also provides cardiac diagnostic testing services as well as billing and collection services on behalf of dispensing physicians.

Forward Looking Statement

This press release may contain forward-looking statements related to the company’s business strategy, outlook, objectives, plans, intentions or goals. The words “may,” “will,” “should,” “plans,” “explores,” “expects,” “anticipates,” “continue,” “estimate,” “project,” “intend,” and similar expressions, identify forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, but their absence does not mean that the statement is not forward-looking. These statements are not guarantees of future performance and are subject to certain risks, uncertainties, and assumptions that are difficult to predict. Actual results could differ materially. Targted Medical Pharma expressly disclaim any obligation or undertaking to update or revise any forward-looking statement contained herein to reflect any change in the company’s expectations with regard thereto or any change in events, conditions or circumstances upon which any statement is based.

 

#               #               #

Targeted Medical Pharma Introduces Medical Food Percura for Dietary Management of Peripheral Neuropathy

Data Shows New Oral Formulation Reduced Symptoms of Pain and Numbness

Los Angeles, December  5, 2012 — Targeted Medical Pharma, Inc. (OTCQB: TRGM) (OTCBB: TRGM), a specialty pharmaceutical company that develops and distributes prescription medical foods to physicians and pharmacies, today reported preliminary data indicating that its new amino acid-based oral formulation PERCURA reduced symptoms of pain and numbness related to peripheral neuropathy in an open-label pilot study.  

“Preliminary study results show medical food PERCURA was able to reduce symptoms found in subjects suffering from peripheral neuropathy related to diabetes,” said William Shell, M.D., CEO and Chief Scientific Officer of Targeted Medical Pharma, Inc. “In 30 percent of the 20 million people suffering from peripheral neuropathy, diabetes is the cause.  Our medical foods treat the nutritional deficiencies found in chronic disease such as diabetes by providing the necessary amino acids to improve clinical outcomes without the negative side effects usually associated with pharmaceutical drugs.”  

The medical food PERCURA reduced symptoms of numbness in subjects an average of 57 percent, after the first 30 days of treatment.  The pilot also reported an average 56 percent reduction in pain among subjects related to peripheral neuropathy after 30 days of treatment.  All subjects are expected to complete the 60-day study by the end of 2012.

About Targeted Medical Pharma, Inc.’s Medical Foods

Targeted Medical Pharma’s medical foods are amino acid based, FDA-regulated medications specially formulated to meet the body’s increased nutritional requirements of certain disease states.  They are a safe and effective option for treating pain syndromes, sleep and cognitive disorders, obesity, hypertension and peripheral neuropathy without harmful side effects.  Physician Therapeutics’ medical foods are available by prescription only and must be administered under the ongoing supervision of a physician.

About  Targeted Medical Pharma, Inc.

Targeted Medical Pharma, Inc., is a specialty pharmaceutical company that develops and sells prescription medical foods to physicians and pharmacies  for the treatment of certain chronic diseases including  pain syndromes, hypertension, obesity,  sleep and cognitive disorders, and peripheral neuropathy.  Based in Los Angeles, the company’s proprietary pharmaceutical therapeutic systems are sold in the United States and the Middle East. The company manufactures ten proprietary Rx only medical foods, as well as 48 convenience packed kits, which pair a medical food and branded or generic pharmaceutical.  These prescription medical foods and therapeutic systems represent a novel approach to the management of certain disease states, focusing on safety and efficacy without the deleterious side effects of traditional, high dose prescription drugs.

Forward Looking Statement

This press release may contain forward-looking statements related to Targeted Medical Pharma’s business strategy, outlook, objectives, plans, intentions or goals. The words “believe,” “may,” “will,” “should,” “plans,” “explores,” “expects,” “anticipates,” “continue,” “estimate,” “project,” “intend,” and similar expressions, identify forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, but their absence does not mean that the statement is not forward-looking. These statements are not guarantees of future performance and are subject to certain risks, uncertainties, and assumptions that are difficult to predict. Actual results could differ materially. Targeted Medical Pharma expressly disclaim any obligation or undertaking to update or revise any forward-looking statement contained herein to reflect any change in the company’s expectations with regard thereto or any change in events, conditions or circumstances upon which any statement is based.

 

###

 

 

Targeted Medical Pharma to Present at 5th Annual LD Micro Growth Conference

Los Angeles, December 4, 2012 – Targeted Medical Pharma, Inc. (OTCQB: TRGM) (OTCBB: TRGM), a specialty pharmaceutical company that develops and distributes prescription medical foods to physicians and pharmacies today announced that members of its executive team are scheduled to present and conduct one-on-one meetings at the LD Micro Growth Conference on December 6, 2012 at 3:30 p.m. Pacific Time. The conference is being held at the Luxe Sunset Bel Air Hotel in Los Angeles, CA.

About Targeted Medical Pharma, Inc.

Targeted Medical Pharma, Inc., a specialty pharmaceutical company that develops and sells prescription medical foods to physicians and pharmacies for the treatment of chronic disease including pain syndromes, obesity, sleep and cognitive disorders. The company manufactures nine proprietary prescription only medical foods, as well as 48 convenience packed kits, which pair a medical food and branded or generic pharmaceutical. These prescription medical foods and therapeutic systems represent a novel approach to the management of certain disease states, focusing on safety and efficacy without the deleterious side effects of traditional, high dose prescription drugs.  Based in Los Angeles, the company’s proprietary pharmaceutical therapeutic systems are currently sold in the United States and the Middle East. Targeted Medical Pharma also provides billing and collection services on behalf of dispensing physicians.

Targeted Medical Pharma Signs Agreement to Assign Certain Accounts Receivables to Cambridge Medical Funding Group

Los Angeles, November 27, 2012Targeted Medical Pharma, Inc. (OTCQB: TRGM) (OTCBB: TRGM), a specialty pharmaceutical company that develops and sells prescription medical foods to physicians and pharmacies for the treatment of chronic disease, today reported the completion of an agreement under which certain accounts receivables will be assigned to New Jersey-based Cambridge Medical Funding Group, LLC (CMFG).

Under the terms of the agreement, medical providers who purchase products from Targeted Medical Pharma will have the option to assign certain accounts receivables from California Workers’ Compensation benefit claims to CMFG at a discounted rate.

“This agreement permits Targeted Medical Pharma to more quickly collect outstanding amounts owed to the company by physicians who will purchase our products, providing us with more opportunities to accelerate growth because of the improved time-to-collection,” said William Shell, M.D., CEO of Targeted Medical Pharma. “Physicians also will benefit from the reduced time spent on the billing and collection process and avoid lengthy delays in workers’ compensation payer reimbursements.”

About Cambridge Medical Funding Group, LLC

Based in Glen Rock, New Jersey, Cambridge Medical Funding Group provides specialized finance solutions to hospitals, surgical centers and medical providers, purchasing receivables and providing guaranteed upfront payments to these providers.

About Targeted Medical Pharma, Inc.

Targeted Medical Pharma, Inc. is a specialty pharmaceutical company that develops and sells prescription medical foods to physicians and pharmacies for the treatment of chronic disease, including pain syndromes, obesity, sleep and cognitive disorders. The company manufactures nine proprietary prescription-only medical foods, as well as 48 convenience packed kits, which pair a medical food and branded or generic pharmaceutical. These prescription medical food products and therapeutic systems represent a novel approach to the management of certain disease states, focusing on safety and efficacy without the deleterious side effects of traditional, high dose prescription drugs. Based in Los Angeles, the company’s proprietary pharmaceutical therapeutic systems are currently sold in the United States, Japan, and the Middle East. Targeted Medical Pharma also provides billing and collection services on behalf of dispensing physicians.

Forward Looking Statement

This press release about an agreement with Medical Funding Group, LLC may contain forward-looking statements related to Targeted Medical Pharma’s business strategy, outlook, objectives, plans, intentions or goals. The words “may,” “will,” “should,” “plans,” “explores,” “expects,” “anticipates,” “continue,” “estimate,” “project,” “intend,” and similar expressions, identify forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, but their absence does not mean that the statement is not forward-looking. These statements are not guarantees of future performance and are subject to certain risks, uncertainties, and assumptions that are difficult to predict. Actual results could differ materially. Targeted Medical Pharma expressly disclaim any obligation or undertaking to update or revise any forward-looking statement contained herein to reflect any change in the company’s expectations with regard thereto or any change in events, conditions or circumstances upon which any statement is based.

# # #

Targeted Medical Pharma Presents at the California Association of Healthcare Facilities’ Annual Convention

Los Angeles, November 14, 2012 — David Silver, M.D., executive vice president of scientific and medical affairs at Targeted Medical Pharma, Inc. (OTCQB: TRGM) (OTCBB: TRGM), discussed the utilization of prescription only medical foods in a skilled nursing setting at this year’s California Association of Health Facilities’ 62nd annual convention, held  in Palm Springs, Calif., on November 12.

The presentation, “Safer and More Effective Pharmacologic Alternatives,” focused on the safety and efficacy of prescription medical foods for the long term management of pain, cognitive and sleep disorders.  Dr. Silver also presented initial data outcomes from an ongoing clinical trial among nursing home patients administered with the medical foods Sentra AM® and Sentra PM®.  Preliminary results among trial participants show an improvement in alertness, memory recall, balance, quality of sleep, sleep latency, sleep duration, as well as a reduction in nighttime awakenings.

“Medical foods provide physicians with a non-addictive and effective prescription alternative to the traditional pharmacologic treatments currently utilized in the skilled nursing setting,” said board certified rheumatologist Dr. Silver. “These medications offer patients a safer way to manage pain, sleep and cognitive disorders, without the risks associated with many single molecule agents currently utilized in this setting.”

Dr. Silver’s presentation can be downloaded by clicking here or visiting http://www.slideshare.net/TMEDPHARMA.

About Targeted Medical Pharma, Inc.

Targeted Medical Pharma, Inc. is a specialty pharmaceutical company that develops and sells prescription medical foods to physicians, and pharmacies for the treatment of chronic disease including pain syndromes, obesity, sleep and cognitive disorders.  The company manufactures nine proprietary prescription only medical foods, as well as 48 convenience packed kits, which pair a medical food and branded or generic pharmaceutical.  These prescription medical food products and therapeutic systems represent a novel approach to the management of certain disease states, focusing on safety and efficacy without the deleterious side effects of traditional, high dose prescription drugs.  Based in Los Angeles, the company’s proprietary pharmaceutical therapeutic systems are currently sold in the United States and Japan.  Targeted Medical Pharma also provides billing and collection services on behalf of dispensing physicians.

Forward Looking Statement

This press release regarding Dr. David Silver’s presentation, “Safer and More Effective Pharmacologic Alternatives,” and initial data results from an ongoing clinical trial among nursing home patients administered with the medical foods Sentra AM® and Sentra PM®,  may contain forward-looking statements related to Targeted Medical Pharma’s business strategy, outlook, objectives, plans, intentions or goals. The words “may,” “will,” “should,” “plans,” “explores,” “expects,” “anticipates,” “continue,” “estimate,” “project,” “intend,” and similar expressions, identify forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, but their absence does not mean that the statement is not forward-looking. These statements are not guarantees of future performance and are subject to certain risks, uncertainties, and assumptions that are difficult to predict. Actual results could differ materially. Targted Medical Pharma expressly disclaim any obligation or undertaking to update or revise any forward-looking statement contained herein to reflect any change in the company’s expectations with regard thereto or any change in events, conditions or circumstances upon which any statement is based.

# # #

Theramine® Featured on Lifetime Television Network’s “The Balancing Act”

Los Angeles, Nov. 13, 2012 – Lifetime Network’s “The Balancing Act,” recently featured the prescription-only medical food Theramine, an effective medication for reducing inflammation and pain associated with chronic pain syndromes.

During the segment, William Shell, M.D., Chief Executive Officer and Chief Scientific Officer of Targeted Medical Pharma, Inc. (OTCQB: TRGM) (OTCBB: TRGM), discussed the benefits of Theramine for the dietary management of syndromes such as fibromyalgia and back pain.

Theramine is a prescription-only medical food regulated by the FDA and specially formulated to meet the increased nutritional requirements of pain syndromes. It is the subject of two large double-blind, randomized, multi-center trials and what we believe is a safe and effective option for treating pain syndromes without harmful side effects.

“The Balancing Act” is a one-hour morning show for women focusing on various topics including health, family and self-empowerment. The segment featuring Dr. Shell discussing Theramine will be rebroadcast on the network Monday, Dec. 10. Viewers can access the segment by visiting (http://www.tmedpharma.com/media/the-balancing-act-v1.php).

About Physician Therapeutics and Targeted Medical Pharma, Inc

Physician Therapeutics is a division of Targeted Medical Pharma, Inc., a specialty pharmaceutical company that develops and sells prescription medical foods to physicians, pharmacies and skilled nursing facilities for the treatment of chronic disease including  pain syndromes, obesity, and sleep and cognitive disorders. The company manufactures nine proprietary medical food products, as well as 48 convenience packed kits, which pair a medical food and branded or generic pharmaceutical. These prescription medical food products and therapeutic systems represent a novel approach to the management of certain disease states, focusing on safety and efficacy without the deleterious side effects of traditional, high dose prescription drugs. Based in Los Angeles, the company’s proprietary pharmaceutical therapeutic systems are currently sold in the United States and Japan. Targeted Medical Pharma also provides billing and collection services on behalf of dispensing physicians.

# # #

Targeted Medical Pharma to Present at Upcoming Investor Conferences

Los Angeles, November 5, 2012 – Targeted Medical Pharma, Inc. (OTCQB: TRGM) (OTCBB: TRGM), a specialty pharmaceutical company that develops and distributes prescription medical foods to physicians, pharmacies and skilled nursing facilities, today announced that members of its executive team are scheduled to present and conduct one-on-one meetings at the following investor conferences:

  • Wednesday, November 7, 2012
    14th Annual SoCal Bio Conference & Exhibition

    Omni Hotel – 251 South Olive Street, Los Angeles, CA
    2:00 p.m. Eastern Time (11:00 a.m. Pacific Time)
  • Thursday, November 29, 2012
    New York Society of Security Analysts’ (NYSSA) 16th Annual Investing in Life Sciences Conference

    NYSSA Conference Facilities – 1540 Broadway, New York, NY
    1:30 p.m. Eastern Time (10:30 a.m. Pacific Time)

A live webcast of the NYSSA presentation will be available at the company’s website at www.tmedpharma.com.

About Targeted Medical Pharma, Inc.

Targeted Medical Pharma, Inc., a specialty pharmaceutical company that develops and sells prescription medical foods to physicians, pharmacies and skilled nursing facilities for the treatment of chronic disease including pain syndromes, obesity, sleep and cognitive disorders. The company manufactures nine proprietary prescription only medical foods, as well as 48 convenience packed kits, which pair a medical food and branded or generic pharmaceutical. These prescription medical food products and therapeutic systems represent a novel approach to the management of certain disease states, focusing on safety and efficacy without the deleterious side effects of traditional, high dose prescription drugs. Based in Los Angeles, the company’s proprietary pharmaceutical therapeutic systems are currently sold in the United States and Japan. Targeted Medical Pharma also provides billing and collection services on behalf of dispensing physicians.

Click here to download press release.

Use of Medical Food Theramine® Found to be Safer and Less Costly Than NSAIDs for Pain Treatment in Elderly Patients

Pharmacoeconomic Analysis Examines the Additional Cost to Prevent
Gastrointestinal Side Effects and Complications

Theramine® Lowered C-reactive protein (CRP) in Clinical Trial

Los Angeles, October 23, 2012 – Medical food Theramine® should be the preferred treatment for pain when compared to NSAIDs (non-steroidal anti-inflammatory drugs) in elderly patients 65 years and older, according to a pharmacoeconomic analysis conducted by Targeted Medical Pharma, Inc. (OTCQB: TRGM) (OTCBB: TRGM) published in the May issue of the Journal of Pharmacy Research.

The scientific economic paper, “Theramine (A Medical Food) Versus Non-Steroidal Anti Inflammatory Agents in Elderly Patients: A Pharmacoeconomic Analysis,” examines the additional cost burden of the strategies to prevent gastrointestinal side effects and complications. A PDF of the full pharmacoeconomic analysis can be viewed by visiting http://bit.ly/TheramineVsNSAIDs.

“Non-steroidal anti-inflammatory drugs are the leading cause of drug induced morbidity and mortality in the United States,” said David S. Silver, M.D., corresponding author of the pharmacoeconomic analysis, and executive VP of medical and scientific affairs at Targeted Medical Pharma, Inc., which develops and distributes prescription medical foods to physicians, pharmacies and skilled nursing facilities. “Gastrointestinal hemorrhage is the most common concern when using NSAIDs, along with hypertension, edema, renal complication and cardiovascular risk, all which occur at higher rates in elderly patients. Patients over the age of 65 with concomitant medications and disease states are the most likely to suffer serious consequence side effects of NSAIDs.”

The analysis found that the actual cost of using Theramine is considerably lower when compared to the total impact of NSAIDs. Excluding the treatment for hepatic, renal and cardiovascular side effects, the annual cost of generic NSAIDs per 100 pain and inflammation patients is $241,500, compared to an annual cost of $211,200 per 100 patients using Theramine.

“Theramine is a prescription only medical food that is used to treat fibromyalgia, acute and chronic neuropathic or inflammatory pain without risk of gastrointestinal or other side effects,” added Dr. Silver. “The higher acquisition costs for Theramine are offset by the reduction in side effects and need for testing and other protective medications in patients over the age of sixty-five taking NSAIDs, making Theramine a preferred choice over non-steroidal anti-inflammatory drugs in elderly patients.”

Methodology

Safety and efficacy data were derived from two large double-blind controlled trials that compared Theramine to low dose naproxen and ibuprofen, as well as other industry published literature. A total of 256 patients across 12 independent sites were randomized for treatment to receive Theramine alone (two capsules twice daily), NSAID or a combination of both. In both studies, Theramine showed statistically significantly greater pain relief than either naproxen at 250mg daily or ibuprofen at 400mg daily. The studies also revealed that Theramine, when administered as a standalone medication and in combination with an NSAID, lowered a statistically significant amount of CRP (C-reactive protein), while an increased CRP level was seen in the naproxen and ibuprofen groups. No side effects from Theramine were reported in the trials and observational reporting after 38,000,000 doses of Theramine showed no gastrointestinal bleeds.

Risk data and rates of gastrointestinal bleeding, morbidity and mortality data were derived from the Medicare database and peer reviewed literature. Medication acquisition costs were determined based on listed average wholesale pricing (AWP). Procedural and hospitalization rates were obtained from the Medicare fee schedule. A cost per life saved analysis was not performed since there is no incremental overall cost increase to the use of Theramine.

Full citation:

“Theramine (A Medical Food) Versus Non-Steroidal Anti Inflammatory Agents in Elderly Patients: A Pharmacoeconomic Analysis.” David S. Silver, M.D.; Elizabeth H. Charuvastra, RN; Lawrence May, M.D.; Stephanie L. Pavlik, CRA; William E. Shell, M.D. Journal of Pharmacy Research (Volume 5, Issue 5); Published online: May 2012.

About Targeted Medical Pharma, Inc.

Targeted Medical Pharma’s medical foods are amino acid based, FDA-regulated medications specially formulated to meet the body’s increased nutritional requirements of disease. They are a safe and effective option for treating pain syndromes, sleep disorders and obesity without harmful side effects. Physician Therapeutics’ medical food products are available by prescription only and must be administered under the ongoing supervision of a physician.

About Targeted Medical Pharma’s Medical Foods

Targeted Medical Pharma, Inc. is a specialty pharmaceutical company that develops and sells prescription medical foods to physicians, pharmacies and skilled nursing facilities for the treatment of chronic disease including pain syndromes, obesity, and sleep and cognitive disorders. Based in Los Angeles, the company’s proprietary pharmaceutical therapeutic systems are sold in the United States and Japan. The company manufactures nine proprietary medical foods, as well as 48 convenience packed kits, which pair a medical food and branded or generic pharmaceutical. These prescription medical food products and therapeutic systems represent a novel approach to the management of certain disease states, focusing on safety and efficacy without the deleterious side effects of traditional, high dose prescription drugs.

Click here to download press release.

Clinical Trials Show Theramine® is Effective at Reducing Inflammation Associated with Chronic Back Pain

Los Angeles, October 18, 2012 – Targeted Medical Pharma, Inc. (OTCQB: TRGM) (OTCBB: TRGM) reported today that the prescription only medical food Theramine is an effective medication for reducing inflammation associated with pain syndromes. Theramine has been the subject of two large double-blind, randomized, multi-center trials, which compared Theramine to low dose naproxen and ibuprofen. 256 subjects participated in the two studies across 20 independent sites that were randomized for treatment to receive Theramine alone (two capsules twice daily), NSAID or a combination of both. In both studies, Theramine showed statistically significantly reduction in inflammation as measured by inflammatory markers and improvement in low back pain than either naproxen at 250mg daily or ibuprofen at 400mg daily.

In the first of the two trials, published in the March, 2012 American Journal of Therapeutics, Theramine when administered as a standalone medication lowered CRP (C-reactive protein) 65% and when administered in combination with a 250mg naproxen lowered CRP 33% compared to baseline. In this study, a 68% increase in CRP levels was seen in the naproxen alone group compared to baseline. The full study can be viewed at http://bit.ly/Theramine-Clinical-Trial.

The second of the two double blind trials compared Theramine to ibuprofen for the treatment of low back pain, which was presented in September, 2012 at PainWeek  in Las Vegas, Nevada and will be presented at the 118th Annual Meeting of AMSUS in Phoenix, Arizona on November 13, 2012. In this study, Theramine when administered as a standalone medication lowered CRP 47% and IL-6 23% and when administered in combination with a once daily 400mg ibuprofen lowered CRP 36% and IL-6 41% compared to baseline. In this study, a 60% increase in CRP was measured in the ibuprofen alone group compared to baseline. No serious side effects were reported in both trials.

“These studies indicate that Theramine is not only an effective pain medication but also an effective anti-inflammatory agent for pain and associated with chronic back pain without the concern of gastrointestinal bleeding or other serious side effects such as hypertension,” said David Silver, M.D., co-author of the study and executive vice president of medical and scientific affairs at Targeted Medical Pharma, Inc.

Full citation:

A double-blind controlled trial of a single dose naproxen and an amino acid medical food Theramine for the treatment of low back pain.”  William E. Shell MD, Elizabeth Charuvastra RN, Lawrence May MD, Debora H. Bullias BS CRA, David S. Silver MD.   American Journal of Therapeutics (Volume 19); Published online: March 2012.

Theramine vs. Ibuprofen for the safe and effective management of chronic low back pain and Inflammation” William E. Shell MD, David S. Silver MD, Fred McCall-Perez PhD, Stephanie Pavlik CRA. The Karen Rieder Federal Nursing Poster Session in conjunction with the 118th Annual Meeting of AMSUS in Phoenix, Arizona.

About Targeted Medical Pharma’s Medical Foods

Targeted Medical Pharma’s medical foods are amino acid based, FDA-regulated medications specially formulated to meet the body’s increased nutritional requirements of disease.  They are a safe and effective option for treating pain syndromes, sleep disorders and obesity without harmful side effects.  Physician Therapeutics’ medical food products are available by prescription only and must administered under the ongoing supervision of a physician.

About Targeted Medical Pharma, Inc

Physician Therapeutics is a division of Targeted Medical Pharma, Inc.,  a specialty pharmaceutical company that develops and distributes prescription medical foods to physicians, pharmacies and skilled nursing facilities for the treatment of chronic disease including  pain syndromes, obesity, and sleep and cognitive disorders.  Based in Los Angeles, the company’s proprietary pharmaceutical therapeutic systems are sold in the United States and Japan. The company manufactures nine proprietary medical food products, as well as 49 convenience pack kits, which pair a medical food and branded or generic pharmaceutical.  These prescription medical food products and therapeutic systems represent a novel approach to the management of certain disease states, focusing on safety and efficacy without the deleterious side effects of traditional, high dose prescription drugs.

To be added to Targeted Medical Pharma’s email list please visit: http://www.tmedpharma.com/ir-request-information

 

Targeted Medical Pharma Commences Public Trading of Its Securities

Shares Begin Trading Over-the-Counter Under Symbol “TRGM”

Los Angeles, October, 12, 2012 – Targeted Medical Pharma, Inc., a specialty pharmaceutical company that develops and distributes prescription medical foods to physicians, pharmacies and skilled nursing facilities, today announced that effective today, its common shares will be trading over-the-counter under the symbol “TRGM” on OTC Market Group’s OTCQB market and the Over-the-Counter Bulletin Board (OTCBB). The company’s publicly traded status follows FINRA’s approval of its 15c2-11 filing.

“We are very excited to begin the next phase of the evolution of our company,” said William Shell, M.D., chief executive officer of Targeted Medical Pharma. “With medical foods gaining wider acceptance among physicians and patients, we believe the company is positioned to enjoy further growth, as we increase marketing efforts for our nine proprietary medical food products and focus on the development of new products that address large patient populations.”

Targeted Medical Pharma, Inc.

Targeted Medical Pharma, Inc., is a specialty pharmaceutical company that develops and sells prescription medical foods to physicians, pharmacies and skilled nursing facilities for the treatment of chronic disease including pain syndromes, obesity, and sleep and cognitive disorders. Based in Los Angeles, the company’s proprietary pharmaceutical therapeutic systems are sold in the United States and Japan. The company manufactures nine proprietary medical foods, as well as 48 convenience packed kits, which pair a medical food and branded or generic pharmaceutical. These prescription medications and therapeutic systems represent a novel approach to the management of certain disease states, focusing on safety and efficacy without the deleterious side effects of traditional, high dose prescription drugs.

Click here to download press release.

####